Posted by Michael Wonder on 08 Jan 2025
Korea's only RET inhibitor, Retevmo, seeks insurance coverage again
6 January 2025 - Lilly Korea is again pursuing reimbursement for Retevmo (selpercatinib), the only RET inhibitor in Korea.
Industry insiders are watching with interest to see if this will bring positive news to Korean cancer patients waiting for insurance coverage.
